Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

April 18, 2025

The clinical trial of the LIVERATION project, funded by Horizon Europe, has reached an important milestone with the recruitment of its 100th patient. The study is already underway in Spain, Italy, Slovenia, and Switzerland, with 8 clinical sites active, and recruitment is ongoing.

This achievement reflects the strong coordination and commitment of a European consortium working to reduce liver cancer recurrence after surgery, through the development and validation of evidence-based strategies.

🌍 A growing European network

The geographical diversity of the trial allows the collection of valuable data across different clinical contexts, strengthening the robustness and applicability of future results. As the remaining associated centres progressively join the active phase of the trial, LIVERATION further establishes itself as a pan-European initiative with real public health impact.

🔭 Looking ahead

Every patient recruited is a step forward — a contribution to scientific knowledge and a chance to improve the outlook and quality of life for those facing liver cancer.

Thanks to all the teams, centres and individuals making this possible.
We continue moving forward with science, commitment and hope.

Liveration